Top Injectable Manufacturer in Moldova – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 5 days ago
- 14 min read
Last Updated: September 1, 2026
TL;DR: Moldova gives the clearest answer this series has produced to the question we always ask first, and the answer is unfavourable but precise, which is worth more than a vague encouragement. Legea nr. 153 of 19 June 2025 defines in its own first article the countries it treats as having the same level of requirements for proving quality, safety and efficacy: the European Economic Area states, the United States, the United Kingdom, Switzerland, Canada, Australia and Japan. India is not among them, and every reliance benefit in the implementing regulation cross-refers to that clause, which closes the ten-working-day accelerated recognition route to an Indian file. Two doors remain open and they matter. The World Health Organization is separately named as a reference authority for prequalified medicines through a collaborative procedure, which makes WHO prequalification the single highest-leverage regulatory asset for this market. And the ordinary national route — full CTD, national laboratory testing, a 210-day statutory clock — is open to anyone. The real constraint, though, is not the dossier at all. It is the price catalogue, because a registered producer price is a precondition for the import authorisation, and the pricing rule is a nine-country external reference basket with a 75% generic ceiling.
Key Takeaways
The list is statutory, it is explicit, and India is not on it. Legea nr. 153 din 19.06.2025 cu privire la medicamente, article 1 paragraph (3), defines “countries with the same level of requirements for proof of the quality, safety and efficacy of medicines” as the states of the European Economic Area, the USA, the United Kingdom, Switzerland, Canada, Australia and Japan. That is a closed enumeration on the face of the law, not a discretionary practice, and the accelerated unilateral-recognition procedure — which runs in ten working days without re-evaluating preclinical and clinical data — is keyed to it. An Indian file goes through the general procedure instead, on a 210-day statutory clock with national laboratory quality control.
The World Health Organization is the one reliance door that is open. Alongside the country list, the regulation names the WHO as a reference authority for prequalified medicines and provides a dedicated collaborative procedure under which the agency accesses the prequalification dossier. For an Indian sterile injectable manufacturer that converts WHO prequalification from a credential into the decisive commercial asset for this market, because it is the only route that avoids re-litigating the full dossier. It also unlocks a waiver of national laboratory testing that a CDSCO GMP certificate alone does not.
Neither Moldova nor India is in PIC/S, and that costs an Indian file twice. We checked all four PIC/S lists — participating authorities, applicants, pre-applicants and former pre-applicants — and neither the Moldovan agency nor CDSCO appears on any of them in any status. Because several reliefs in the Moldovan regulation are keyed to PIC/S participation, an Indian file loses them: documents from Indian authorities require apostille or legalisation where EU and PIC/S documents verifiable in a public register are accepted as plain copies, and full national laboratory testing applies where a PIC/S-inspected site would be exempt. Budget the authentication chain and the sample analysis as real line items.
The commercial gate is the price catalogue, not the marketing authorisation. Under Hotararea Guvernului nr. 295 of 17 May 2023 a producer price must be approved and registered before a product can be placed on the market, and the catalogue entry is expressly the basis on which import authorisations are issued — no registered price, no imports. The reference basket is nine named countries with populations not exceeding 25 million: Romania, Bulgaria, Serbia, Croatia, Slovakia, Lithuania, Hungary, the Czech Republic and Greece. The rule is not lowest-of: where prices exist in four or more, the lowest is excluded and the next three are averaged. A generic may not exceed 75% of the approved originator price, and annual increases are capped at 15%.
Introduction: Why Moldova Demands a Premium Injectable Manufacturer in Moldova
The question we put to every market before writing a word is whether it operates a reliance or recognition route keyed to a named list of regulators, and whether India is on that list. Most answers require reading three instruments and inferring. Moldova's answer is in the third paragraph of the first article of its medicines law, in a single sentence, and it is unambiguous. Legea nr. 153 of 19 June 2025 states that for the purposes of that law the countries with the same level of requirements for proof of the quality, safety and efficacy of medicines are the states of the European Economic Area, the United States, the United Kingdom of Great Britain and Northern Ireland, Switzerland, Canada, Australia and Japan. India is not in that sentence, and the accelerated procedure that grants a marketing authorisation in ten working days without substantive re-evaluation of the preclinical and clinical data is cross-referenced to it throughout the implementing regulation.
There is a trap here that we want to name before going further, because it catches people who know the region. Moldova is an EU candidate country with an Association Agreement, and its 2025 law expressly transposes parts of Directive 2001/83/EC and Regulation (EU) 536/2014. It would be natural to conclude that EU-style mutual recognition already applies, and it does not. What Moldova has done is transpose the substantive content of EU pharmaceutical law into national law while operating unilateral reliance on a list it names itself. There is no mutual recognition agreement, and the implementing regulation contains a clause repealing certain national-only provisions only on the date of Moldova's accession to the European Union — which is a plain statement that the national regime persists until then. One further honesty is owed. That implementing regulation sat in the Government's April 2026 session file carrying a blank decision number and date, and we could not confirm publication in the Monitorul Oficial. The statute is in force; the detailed procedure below is drawn from a draft we have flagged as such wherever we rely on it.
What Sets a World-Class Injectable Manufacturer in Moldova Apart
The mechanics of an Indian file are knowable and the awkward parts are mostly logistical rather than legal. The dossier is CTD in five modules, with a national Moldovan Module 1 rather than the EU one, and the format requirement contains a detail that surprises people who assume European alignment means European practice: electronic common technical document format is not mandatory, and the instrument specifies Module 1 on paper with the remaining modules supplied electronically in a single copy. Dossier documentation may be in Romanian, English or Russian, which is unusually accommodating, but the product information is not — the summary of product characteristics, the patient leaflet and the labelling must be in Romanian. There is a useful carve-out worth knowing about: Romanian-language product information approved in Romania can be accepted in Moldova, conditional on the same batches being marketed in both countries and on changes being filed in Moldova after Romanian approval. Registration runs for five years, renewal must be requested at least six months before expiry, and stock manufactured and imported before expiry may be distributed until batch expiry but no more than twelve months beyond.
Then there is the asymmetry that a PIC/S absence creates, and it is the operational sting of this market. The regulation operates a two-tier authentication rule. Documents issued by competent authorities of EU member states or by PIC/S participating authorities, verifiable in an official public electronic register, are accepted as plain copies with no apostille and no legalisation. Documents issued by the authorities of any other state — which means India — require apostille or legalisation, unless the agency can confirm authenticity directly with the issuing authority. The same rule governs manufacturing authorisations and GMP certificates. The second half of the same asymmetry concerns testing: national laboratory quality control at registration is waived for products from the article 1(3) countries, for WHO-prequalified products with confirmed dossier identity, and for products whose manufacturing site has been inspected by a PIC/S participating authority evidenced by that authority's GMP certificate. An Indian site with a CDSCO certificate qualifies for none of those on GMP grounds, so the default is full laboratory testing — and that means supplying samples sufficient for three complete analyses together with reference substances, impurities, degradation products and, in a requirement that catches everyone the first time, the chromatographic column.
Quality Systems Behind Every Injectable Supplied to Moldova
The GMP evidence set is demanding in breadth rather than in kind. A GMP certificate is required for every manufacturer involved in the product — the active substance, the bulk and the finished form — issued in accordance with World Health Organization recommendations and stating the date and results of the last inspection, with a European Pharmacopoeia certificate of suitability accepted as the alternative for an active substance. Manufacturing authorisations are required for all of those manufacturers, and a certificate of a pharmaceutical product in the original, drawn per WHO recommendations, is required as well. There is also a substantive prerequisite that catches contract manufacturers: the product generally has to be authorised in the country of the manufacturer or of the marketing authorisation holder, with the derogation from that requirement available only for centrally authorised EU products, products authorised in one of the article 1(3) countries, or WHO-prequalified products. In practice an Indian manufacturer will normally need to show a CDSCO marketing authorisation for the exact product, which is a planning constraint rather than an obstacle but needs to be sequenced early.
Inspection of the foreign site is discretionary but real, and it is not a formality. The medicines commission may require an inspection of manufacturing sites; refusing one terminates the procedure; and the procedure can be suspended for up to twelve months pending the inspection report. Set against that, we should be clear about what we could not establish, because a sterile injectables business will care about it more than about anything else on this page. We did not read Moldova's requirements on batch release, on import testing or retesting on entry, or on any local equivalent of the European qualified person, and we did not read the import authorisation and wholesale licensing regulations at all. Those are material gaps for this product class and we are flagging them rather than filling them with plausible-sounding sentences. Nor do we quote a single fee. The tariff instrument is Hotararea Guvernului nr. 348 of 2014, and its second annex — which contains the actual figures — was not retrievable, so we have no verified registration, renewal, variation, inspection, price-registration or import figure in any currency, and we would rather say so than repeat a number from a consultancy page.
Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry.
Why Farbe Firma is the Trusted Injectable Manufacturer in Moldova for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries. We work in CTD and ACTD format, run HPLC, GC, LAL endotoxin testing and Karl Fischer determination in-house, and hold ICH Q1A and Q1B stability programmes behind our files. For Moldova specifically, the sequencing advice we would give a buyer is unusual and we think it is the most valuable thing in this article. Do not start with the dossier. Start with whether the product can be brought under World Health Organization prequalification, because the collaborative procedure keyed to WHO prequalification is the only reliance route available to an Indian file in this market, and it simultaneously resolves the national laboratory testing question that the PIC/S absence otherwise leaves open. Where prequalification is not realistic for a given product, the general 210-day route is perfectly workable — but it should be entered with the authentication chain and the sample-and-column analytical package budgeted from the start rather than discovered at month four.
Now the part that decides whether a Moldovan launch makes money, which is pricing, and here the primary instrument is unusually explicit. Under Hotararea Guvernului nr. 295 of 17 May 2023 a producer price must be approved and entered in the national catalogue, and the catalogue serves expressly as the basis for issuing import authorisations and for placing products on the pharmaceutical market. That is the sentence to internalise: no registered price means no import licence, whatever your marketing authorisation says. The reference basket is nine named countries, each defined as having a population not exceeding 25 million — Romania, Bulgaria, Serbia, Croatia, Slovakia, Lithuania, Hungary, the Czech Republic and Greece. The comparison rule is more forgiving than the lowest-price rules common elsewhere but it is not generous: where the product is priced in four or more of the nine, the lowest is excluded and the average of the next three is taken; with three, the lowest is excluded and the remaining two averaged; with two, the lowest is excluded and the higher taken. A generic may not exceed 75 per cent of the approved originator price and is re-evaluated if it later does. Prices are set in Moldovan lei at the average official rate for the twelve months before filing, annual increases are capped at 15 per cent, a price is valid for one year and extendable to three by negotiation, and a voluntary withdrawal triggers a twelve-month lockout before you may reapply.
For a new Indian generic the fallback cascade is where the negotiation actually happens, and it contains a fact worth planning around. A product with no price in any of the nine reference countries is compared first against the average of prices already in the national catalogue for the same international non-proprietary name; if only one such product exists and the manufacturer rejects that price, direct negotiation opens; if no same-INN product exists, the comparison runs to the producer price registered in the country of origin — which for us means India. An Indian domestic price can therefore become the anchor for a Moldovan one, which is an argument for thinking about domestic and export pricing as a single problem rather than two. The negotiating body is interinstitutional, with three agency members, one from the Ministry of Health and one from the national health insurance company, chaired by the agency's director general, meeting monthly and concluding within thirty working days, and it looks at whether the product sits on the essential medicines list and the compensated medicines list. Downstream, the standing 1997 regulation on price formation caps the total commercial mark-up at 40 per cent, of which no more than 15 points may go to importers and wholesalers and no more than 25 to pharmacies — though we should say that the consolidated text we read dates from 2012 and still cross-refers to instruments since replaced, so confirm currency before modelling. As for whether the market is worth the work: Moldova had about 2.4 million people and gross national income per capita of about USD 6,890 in 2024, spending roughly 6.74 per cent of GDP on health at about USD 452 per person, with out-of-pocket spending at 27.5 per cent in 2023 and falling from nearly 36 per cent in 2019. The clinical case is stronger than the demographic one. World Health Organization data for 2024 shows tuberculosis incidence at 64 per 100,000, about 2,000 cases — but 670 of those were rifampicin-resistant, amounting to 28 per cent of new cases and 50 per cent of previously treated ones, among the highest rates in the European region. For an injectable manufacturer with second-line and supportive-care capability, that is the conversation to have. One caution on arithmetic: the World Health Organization uses a population denominator of about 3.03 million for Moldova where the World Bank uses about 2.40 million, a divergence of roughly a quarter that almost certainly reflects Transnistria, so never derive a per-capita figure across the two sources.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is India on Moldova's list of recognised countries, and what does that mean for us?
No, and the exclusion is on the face of the statute rather than buried in practice. Article 1 paragraph (3) of Legea nr. 153 of 19 June 2025 defines the countries with an equivalent level of requirements as the European Economic Area states, the USA, the United Kingdom, Switzerland, Canada, Australia and Japan. India is absent, and every reliance benefit in the implementing regulation cross-refers to that clause. The practical consequence is that the accelerated unilateral-recognition procedure — ten working days, no substantive re-evaluation of preclinical and clinical data, no national laboratory testing, and unlimited validity after the first five-year renewal — is not available to an Indian file. What is available is the general procedure on a 210-day statutory clock with full CTD and national laboratory quality control, and, far more valuably, the collaborative procedure keyed to World Health Organization prequalification, which is named separately as a reference route and is open regardless of the country list.
Do we need our Indian documents apostilled?
Yes, on the regulation as drafted, and this is a direct consequence of the PIC/S position rather than anything specific to India. The rule is two-tier. Documents issued by EU member-state competent authorities or by PIC/S participating authorities that can be verified in an official public electronic register are accepted as plain copies, with no apostille and no legalisation required. Documents issued by the authorities of any other state require apostille or legalisation, unless the agency is able to confirm authenticity directly with the issuing authority. The same rule applies to manufacturing authorisations and to GMP certificates. We verified against all four PIC/S lists that neither the Moldovan agency nor CDSCO appears in any status — not member, not applicant, not pre-applicant, not former pre-applicant — so there is no shortcut in either direction today. Treat authentication as a lead-time item and start it before the dossier is finished.
Will our WHO-GMP certificate spare us national laboratory testing?
On GMP grounds alone, no. The waiver from laboratory quality control at registration is granted for products registered centrally in the EU or in one of the article 1(3) countries, for products whose manufacturing site has been inspected by a PIC/S participating authority as evidenced by that authority's GMP certificate, for WHO-prequalified products where dossier identity is confirmed, and for unchanged renewals. An Indian site holding a CDSCO WHO-GMP certificate meets none of the GMP-based conditions, so full testing is the default. Note the route that does work: WHO prequalification qualifies on its own terms. If testing applies, plan for it properly — the requirement is samples sufficient for three complete analyses plus reference substances, impurities, degradation products and the chromatographic column, which is a genuine analytical package and not a token submission. A GMP certificate is still required for every manufacturer involved, stating the date and results of the last inspection, and the agency retains discretion to inspect the site.
What is the real commercial constraint in Moldova?
Price registration, without much competition for the title. Under Hotararea Guvernului nr. 295 of 17 May 2023 the producer price must be approved and entered in the national catalogue, and that catalogue is expressly the basis on which import authorisations are issued and products are placed on the market — so a marketing authorisation without a registered price does not let you ship. The basket is nine countries with populations not exceeding 25 million: Romania, Bulgaria, Serbia, Croatia, Slovakia, Lithuania, Hungary, the Czech Republic and Greece. The rule is not simply the lowest price: with four or more reference prices the lowest is excluded and the next three averaged, with three the lowest is excluded and two averaged, with two the lowest is excluded and the higher taken. Generics are capped at 75 per cent of the approved originator price. Annual increases are capped at 15 per cent, prices run for a year and can be extended to three by negotiation, and withdrawing a price voluntarily locks you out for twelve months. Where no reference price exists the comparison falls back to same-INN prices already in the catalogue and then to your registered price in India, so treat Indian and export pricing as one decision.
What did you not manage to verify about Moldova?
Several things, and they are worth listing because two of them matter commercially. First, the implementing Government Decision that sets out the five procedures was still a draft in the document we read, carrying a blank number and date in the Government's April 2026 session file, and we could not confirm publication in the Monitorul Oficial; the 2012 ministerial order that probably still governs in practice we were not able to read at all. Everything procedural above should be read with that caveat. Second, we could not establish whether foreign manufacturers may bid directly into centralised hospital procurement or must go through a locally licensed distributor, and we obtained no prequalification rules — a real gap on a commercially important question. Third, no fee figure of any kind was verified, because the tariff annexe was not retrievable. Fourth, we did not investigate batch release, import retesting or any qualified-person equivalent, which for sterile injectables specifically is a gap we would want closed before committing. We also obtained no cardiovascular, non-communicable disease or cancer figures, and no data on market size or on whether any Indian manufacturer currently holds a Moldovan authorisation. On trade we can give you both sides and the discrepancy: India-reported HS30 exports to Moldova were about USD 4.07 million in 2022, USD 3.64 million in 2023 and USD 4.30 million in 2024, while the Moldova-reported mirror was about USD 10.55 million, USD 7.35 million and USD 9.24 million. Moldova consistently reports around double, and we are not going to explain that away or average it.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments